Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ifupinostat
- Development stage
- Phase 3
- Lead developer
- BeBetter Med
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ifupinostat is a novel, orally available small molecule that acts as a dual inhibitor of phosphatidylinositol 3-kinase alpha (PI3Kα) and histone deacetylases (HDACs). By simultaneously inhibiting both PI3Kα and HDACs, ifupinostat disrupts key tumor cell signaling networks involved in cancer cell proliferation and survival. This dual-targeting approach is designed to enhance antitumor efficacy by blocking two critical pathways implicated in oncogenesis. Ifupinostat has demonstrated potent nanomolar inhibitory activity against PI3Kα (IC50 <0.1 μM) and HDACs (IC50 0.1–1 μM)[7][4][9]. It is being developed primarily for the treatment of hematologic malignancies such as relapsed/refractory diffuse large B-cell lymphoma[8][4].
- Brand names
- Betlin
- Other names
- ifupinostat hydrochloride
02
Targets
HDAC (HDAC family)PIK3CA (Phosphoinositide 3-kinase alpha)
Beyond the preview
Go deeper on ifupinostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ifupinostat.